TS. DR. RAIHANA ZAHIRAH EDROS
Senior Lecturer Universiti Malaysia Pahang
Faculty of Chemical and Process Engineering Technology
rzahirah@ump.edu.my

NO	NAME	INSTITUTION	FACULTY/SCHOOL/ CENTRE/UNIT
1	Rajaletchumy A/P Veloo Kutty	UMP	Faculty of Chemical and Process Engineering Technology
2	Heilly Chong @ Azlinda Abd. Halik		Protein Science
3	Ong Sheau Ching		Protein Science
2	Mohd Fazli Bin Ismail	UMP
3	FADZILAH @ ADIBAH BINTI ABD MAJID	UMT	Institut Bioteknologi Marin

2 years (15 August 2017 - 14 August 2019)

One way to enhance the synthesis of recombinant protein is to improve its expression level. The main objective of this study is to elucidate the mechanism that regulates the expression of p110 in different producers when stimulated by human inflammatory cytokines such Tumor Necrosis Factor alpha (TNF-α) and Human Interleukin (IL)-1β. Upon stimulation, the concentration of product is tested by using Enzyme-Linked Immunosorbent Assay (ELISA) while the expression of p110 gene and protein are quantified through quantitative Polymerase Chain Reaction (qPCR) and Western Blot respectively. This study is significant in investigating the mechanism of recombinant protein under the stimulation of p100. The expected outcome for this work is an improved understanding of how p100 expression influences the synthesis of recombinant protein.

1. To stimulate the high and low recombinant cell producers with inflammatory cytokines such as Tumour Necrosis Factor alpha (TNF-α) and human interleukin (IL)-1β.
2. To study the effect of inflammatory cytokines on the production of recombinant protein in the high and low producers.
3. To investigate the correlation that exist between the expression of catalytic subunit of delta polypeptide, p110 and the expression of recombinant protein.

1. Publication :
   • 2 indexed journal
   • 2 scopus conference paper

Recombinant proteins such as monoclonal antibodies can be categorized as the high value products. There are 12 monoclonal antibodies in which the patent is about to end by 2020 including betacizumab (patent ends 2022) and trastuzumab (patent ends 2019) that will generate over RM 3.2 billion of revenue each year. These products, if can be produced locally will boost the local export worth about RM 435 billion. The income generation under the Healthcare NKEA will benefit Malaysia in terms of robust GNI per capita and job growth (economic impact), better healthcare assets and professionals (infrastructure impact) and higher quality and faster care (patient, thus community impact). There are many theories on how the cells behave under different environment and circumstances that could be generated resulting from this work. A novel vector design with p110 incorporated will increase the specific productivity of recombinant cell lines while keeping its stability at par.